BIOMAT Database Logo BIOMAT Database Logo

Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients. 2023

Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Department of Medical Oncology, Bern University Hospital, University of Bern, Bern, Switzerland.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072916 Peripheral Blood Stem Cells Hematopoietic stem cells found in peripheral blood circulation. Peripheral Blood Stem Cell,Peripheral Stem Cell,Peripheral Stem Cells,Stem Cell, Peripheral,Stem Cells, Peripheral
D001596 Benzylamines Toluenes in which one hydrogen of the methyl group is substituted by an amino group. Permitted are any substituents on the benzene ring or the amino group. Phenylmethylamine,alpha-Aminotoluene,alpha Aminotoluene
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell
D019650 Hematopoietic Stem Cell Mobilization The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization. Stem Cell Mobilization,Mobilization, Stem Cell
D036102 Peripheral Blood Stem Cell Transplantation Transplantation of PERIPHERAL BLOOD STEM CELLS. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW. Peripheral Stem Cell Transplantation,Stem Cell Transplantation, Peripheral,Transplantation, Peripheral Stem Cell

Related Publications

Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma.
November 2012, Hematology reports,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma.
October 2017, International journal of hematology,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
[Efficacy of plerixafor in autologous peripheral blood stem cell collection].
January 2019, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection.
June 2021, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
May 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.
October 2020, Haematologica,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.
January 2011, Advances in hematology,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
January 2022, Cytotherapy,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Efficacy and safety of plerixafor in pediatric cancer patients undergoing peripheral blood stem cell harvest for autologous hematopoietic stem cell transplant.
August 2023, Blood cell therapy,
Melanie Maechler, and Ulrike Bacher, and Michael Daskalakis, and Henning Nilius, and Michael Nagler, and Behrouz Mansouri Taleghani, and Barbara Jeker, and Thomas Pabst
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
December 2014, Journal of clinical apheresis,
Copied contents to your clipboard!